Literature DB >> 1451258

Endothelial dysfunction in patients with chest pain and normal coronary arteries.

A A Quyyumi1, R O Cannon, J A Panza, J G Diodati, S E Epstein.   

Abstract

BACKGROUND: A subgroup of patients with chest pain and angiographically normal epicardial coronary arteries have reduced dilator response to metabolic or pharmacological stimuli, but the mechanisms responsible for this reduced dilator response are unknown. In this study, we have investigated whether microvascular endothelial dysfunction is a cause of the observed reduced vasodilator reserve. METHODS AND
RESULTS: The functional response of the microvasculature was studied with rapid atrial pacing at 150 beats per minute. Fifty-one patients, 20 hypertensive and 31 normotensive, with chest pain and normal epicardial coronary arteries (< 10% stenosis) were studied. Endothelial function was tested with incremental infusions of acetylcholine to achieve estimated intracoronary concentrations ranging from 10(-7) M to 10(-5) M. Endothelium-independent smooth muscle vasomotion was measured using intracoronary sodium nitroprusside. Endothelial dysfunction of epicardial coronary arteries, demonstrated as severe (> 50%) constriction with < 10(-5) M acetylcholine concentration, was evident in five patients (10%). In the remaining 46 patients, coronary blood flow increased with acetylcholine (mean, 78 +/- 43%) and atrial pacing (mean, 51 +/- 37%), and coronary vascular resistance decreased by 35 +/- 16% and 29 +/- 14%, respectively, but the responses were heterogeneous. There was a correlation between the coronary resistance change with acetylcholine and the change with atrial pacing: r = 0.68, p < 0.001 in these 46 patients. Thus, patients with depressed dilation with atrial pacing had reduced endothelium-dependent dilation with acetylcholine, and vice versa. However, the microvascular dilation caused by sodium nitroprusside was not significantly different between patients with and those without reduced dilation with atrial pacing, indicating that the vasodilator defect was not caused by smooth muscle dysfunction. There were no differences in the vasodilator responses with atrial pacing, acetylcholine, or nitroprusside between normotensive and hypertensive patients. Multivariate regression analysis was performed to determine whether age, sex, serum cholesterol level, hypertension, presence of mild epicardial vessel atherosclerosis, resting left ventricular function, change in left ventricular ejection fraction with exercise, vasodilation with acetylcholine, and vasodilation with sodium nitroprusside were independently related to the vasodilator response to atrial pacing. Only the change in coronary vascular resistance with acetylcholine was independently correlated with the change in resistance with atrial pacing: R2 = 0.46, p < 0.0001.
CONCLUSIONS: Patients with chest pain, normal epicardial coronary arteries, and reduced vasodilation in response to atrial pacing appear to have associated endothelial dysfunction of the coronary microvasculature. Thus, microvascular endothelial dysfunction may contribute to the reduced vasodilator reserve with atrial pacing and anginal chest pain in these patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1451258     DOI: 10.1161/01.cir.86.6.1864

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  41 in total

1.  The role of myocardial perfusion imaging in vascular endothelial dysfunction.

Authors:  V Dilsizian
Journal:  J Nucl Cardiol       Date:  2000 Mar-Apr       Impact factor: 5.952

2.  Effect of L-arginine administration on myocardial thallium-201 perfusion during exercise in patients with angina pectoris and normal coronary angiograms.

Authors:  H Fujita; H Yamabe; M Yokoyama
Journal:  J Nucl Cardiol       Date:  2000 Mar-Apr       Impact factor: 5.952

Review 3.  Role of the vascular endothelium in patients with angina pectoris or acute myocardial infarction with normal coronary arteries.

Authors:  J Sztajzel; F Mach; A Righetti
Journal:  Postgrad Med J       Date:  2000-01       Impact factor: 2.401

4.  Noninvasive prediction of coronary artery disease progression by comparison of serial exercise electrocardiography and dipyridamole stress echocardiography.

Authors:  Olaf Rodriguez; Eugenio Picano; Silvio Fedele; Martha Morelos; Mario Marzilli
Journal:  Int J Cardiovasc Imaging       Date:  2002-04       Impact factor: 2.357

5.  Regional myocardial perfusion defects during exercise, as assessed by three dimensional integration of morphology and function, in relation to abnormal endothelium dependent vasoreactivity of the coronary microcirculation.

Authors:  T H Schindler; E Nitzsche; N Magosaki; I Brink; M Mix; M Olschewski; U Solzbach; H Just
Journal:  Heart       Date:  2003-05       Impact factor: 5.994

6.  Assessment of coronary flow reserve by sestamibi imaging in patients with typical chest pain and normal coronary arteries.

Authors:  Giovanni Storto; Anna Rita Sorrentino; Teresa Pellegrino; Raffaele Liuzzi; Mario Petretta; Alberto Cuocolo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-06       Impact factor: 9.236

Review 7.  Control of coronary blood flow by autacoids.

Authors:  E Bassenge
Journal:  Basic Res Cardiol       Date:  1995 Mar-Apr       Impact factor: 17.165

Review 8.  Syndrome X--angina and normal coronary angiography.

Authors:  A Chauhan
Journal:  Postgrad Med J       Date:  1995-06       Impact factor: 2.401

9.  Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis.

Authors:  A A Quyyumi; N Dakak; N P Andrews; S Husain; S Arora; D M Gilligan; J A Panza; R O Cannon
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

10.  Prognostic predictors and outcomes in patients with abnormal myocardial perfusion imaging and angiographically insignificant coronary artery disease.

Authors:  Fadi Alqaisi; Firas Albadarin; Zehra Jaffery; Leonidas Tzogias; Muath Dawod; Gordon Jacobsen; Karthik Ananthasubramaniam
Journal:  J Nucl Cardiol       Date:  2008-07-31       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.